Alonso Krangle LLP is currently offering FREE Fosamax lawsuit evaluations to anyone who suffered a femur fracture while using this drug.
Melville, New York (PRWEB) September 25, 2012
Alonso Krangle LLP, a national law firm and NY personal injury firm focused on fighting for the rights of serious personal injury victims of harmful drug side effects, announce they have filed a Fosamax lawsuit on behalf of a woman who suffered a fracture of her right femur, allegedly as a result of her use of Fosamax. The Fosamax femur fracture lawsuit, which was filed on September 12, 2012 in New Jersey Superior Court, Atlantic County, names Merck Sharp & Dohme Corp. f/k/a Merck & Company, Inc. as Defendant (Case No. ATL-L-006286-12).
Alonso Krangle is currently offering FREE Fosamax lawsuit consultations to anyone who suffered a femur fracture that may be related to their use of Fosamax. To discuss a potential claim with one of the experienced and compassionate Fosamax femur fracture lawyers at Alonso Krangle LLP, please contact us at 1-800-403-6191 or visit our website, FightForVictims.com.
According to the new Fosamax femur fracture lawsuit filed by Alonso Krangle, the Plaintiff, a woman from Castle Pines, Colorado, suffered a right femur fracture on November 16, 2011, allegedly due to Fosamax. The complaint notes that over the past few years, there have been an increasing number of reports of patients suffering stress factures as a result of severely suppressed bone turnover caused by long-term Fosamax use. The complaint further alleges that the Defendants knew of the significant risk of severely suppressed bone turnover, brittle bones, and multiple stress fractures associated with long-term use of Fosamax, but did not sufficiently warn consumers, the Plaintiff, her doctors or the medical community. Because of her use of Fosamax, the complaint alleges the Plaintiff suffered severe medical pain and suffering, and has and will sustain permanent injuries and emotional distress, along with economic losses due to medical expenses, and living-related expenses due to her new life style. The complaint further alleges that she would not have used Fosamax had the Defendants properly disclosed the risks or side effects associated with its long-term use.
Fosamax, marketed by Merck & Co., is approved to treat osteoporosis and other bone weakening diseases. In October 2010, the U.S. Food & Drug Administration (FDA) ordered the makers of Fosamax and other bisphosphonates to add information about the risk of atypical femur fractures to the “Warnings and Precautions” section of their labels. The FDA ordered the label change after a study involving over 300 women who sustained such fractures found that 94 percent had taken a bisphosphonate. Most had been on the drugs for five years or more. [fda.gov/Drugs/DrugSafety/ucm229009.htm]
Since the FDA ordered the label change, more evidence has emerged linking long-term use of Fosamax to an increased risk of femur fractures. In May, an analysis published in the New England Journal of Medicine (NEJM) by FDA researchers found little benefit from the long-term use of bisphosphonates (longer than five years). According to the study, long-term use of Fosamax and similar drugs has raised questions because of their potential association with serious side effects, including atypical thigh fractures, Osteonecrosis of the Jaw (ONJ or Dead Jaw Syndrome), and esophageal cancer. [nejm.org/doi/full/10.1056/NEJMp1202619]
In June, a study published in the Archives of Internal Medicine reported that the likelihood that a patient will experience an atypical femur fracture increases the longer they use bisphosphonates like Fosamax. According to the report, 82 percent of the patients with atypical fractures had been treated with bisphosphonates, like Fosamax, compared with about 6 percent of the patients with classic fractures.
Hundreds of women throughout the country have filed Fosamax femur fracture lawsuits seeking compensation for their pain and suffering. Many of those complaints have been consolidated in a Mass Tort proceeding (In re: Fosamax Litigation - No. 282 NJ. Super. Ct.) in the Superior Court of New Jersey, Law Division, Atlantic County. Hundreds of other Fosamax lawsuits are pending in a multidistrict litigation in U.S. District Court, District of New Jersey before the Honorable Garrett E. Brown, Jr. (“MDL No. 2243).
Alonso Krangle LLP offers free lawsuit evaluations to any Fosamax user who suffered a femur fracture that could be associated with long-term use of this drug. To discuss a potential claim with one of the experienced and compassionate Fosamax femur fracture lawyers at Alonso Krangle LLP, please contact us at 1-800-403-6191 or visit our website, FightForVictims.com.
About Alonso Krangle LLP
Andres Alonso and David Krangle, attorneys with almost 40 years of collective legal experience, have focused their law practice on the handling of significant personal injury cases, defective drug and medical device litigation, construction site accidents, nursing home abuse, medical negligence, qui tam/whistleblower actions and consumer fraud cases. A national law firm representing injured victims throughout the U.S., Alonso Krangle LLP is headquartered in Long Island, New York, with offices in New York City, and New Jersey.
For more information about Alonso Krangle or to join the fight and be a part of our team, please contact us at 1-800-403-6191 or visit our website, http://www.FightForVictims.com.
Alonso Krangle LLP
445 Broad Hollow Road
Melville, New York 11747